175 related articles for article (PubMed ID: 35654000)
1. Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer.
Kwon MR; Chu J; Kook SH; Kim EY
Clin Imaging; 2022 Sep; 89():1-9. PubMed ID: 35654000
[TBL] [Abstract][Full Text] [Related]
2. Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients: Factors of radiologic-pathologic discordance.
Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY; Yoon GY
Eur J Radiol; 2019 Sep; 118():114-121. PubMed ID: 31439230
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
4. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
[TBL] [Abstract][Full Text] [Related]
5. Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study.
Kwak L; Santa-Maria C; Di Carlo P; Mullen LA; Myers KS; Oluyemi E; Panigrahi B; Rossi J; Ambinder EB
Clin Imaging; 2023 Sep; 101():105-112. PubMed ID: 37327550
[TBL] [Abstract][Full Text] [Related]
6. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
7. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment MRI features associated with diagnostic accuracy of post-treatment MRI after neoadjuvant chemotherapy.
Eun NL; Gweon HM; Son EJ; Youk JH; Kim JA
Clin Radiol; 2018 Jul; 73(7):676.e9-676.e14. PubMed ID: 29567270
[TBL] [Abstract][Full Text] [Related]
10. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
Weber JJ; Jochelson MS; Eaton A; Zabor EC; Barrio AV; Gemignani ML; Pilewskie M; Van Zee KJ; Morrow M; El-Tamer M
J Am Coll Surg; 2017 Dec; 225(6):740-746. PubMed ID: 28919579
[TBL] [Abstract][Full Text] [Related]
11. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
12. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
van Ramshorst MS; Loo CE; Groen EJ; Winter-Warnars GH; Wesseling J; van Duijnhoven F; Peeters MTV; Sonke GS
Breast Cancer Res Treat; 2017 Jul; 164(1):99-106. PubMed ID: 28432515
[TBL] [Abstract][Full Text] [Related]
13. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study.
Bitencourt AGV; Pires BS; Calsavara VF; Negrão EMS; Souza JA; Graziano L; Guatelli CS; Makdissi FB; Sanches SM; Tavares MC; Osório CABT; De Brot M; Marques EF; Chojniak R
Eur Radiol; 2021 Dec; 31(12):9520-9528. PubMed ID: 34036420
[TBL] [Abstract][Full Text] [Related]
15. Human Epidermal Growth Factor 2-positive Breast Cancer with Mammographic Microcalcification: Relationship to Pathologic Complete Response after Neoadjuvant Chemotherapy.
Mazari FAK; Sharma N; Dodwell D; Horgan K
Radiology; 2018 Aug; 288(2):366-374. PubMed ID: 29786482
[TBL] [Abstract][Full Text] [Related]
16. Comparison of
Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
[No Abstract] [Full Text] [Related]
17. MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.
Sener SF; Sargent RE; Lee C; Manchandia T; Le-Tran V; Olimpiadi Y; Zaremba N; Alabd A; Nelson M; Lang JE
J Surg Oncol; 2019 Nov; 120(6):903-910. PubMed ID: 31400007
[TBL] [Abstract][Full Text] [Related]
18. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications.
Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY
Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651
[TBL] [Abstract][Full Text] [Related]
19. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
20. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]